Switch theme
Sign up to access all valuation multiples
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.
2011
1.5K+
LTM Revenue $204M
Last FY EBITDA -$7.4M
$763M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AIM Vaccine has a last 12-month revenue (LTM) of $204M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, AIM Vaccine achieved revenue of $164M and an EBITDA of -$7.4M.
AIM Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AIM Vaccine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $204M | XXX | $164M | XXX | XXX | XXX |
| Gross Profit | $155M | XXX | $122M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$7.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$26.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -16% | XXX | XXX | XXX |
| Net Profit | -$23.8M | XXX | -$35.4M | XXX | XXX | XXX |
| Net Margin | -12% | XXX | -22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $169M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AIM Vaccine's stock price is HKD 4 (or $0).
AIM Vaccine has current market cap of HKD 4.6B (or $590M), and EV of HKD 6.0B (or $763M).
See AIM Vaccine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $763M | $590M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AIM Vaccine has market cap of $590M and EV of $763M.
AIM Vaccine's trades at 4.7x EV/Revenue multiple, and -103.3x EV/EBITDA.
Equity research analysts estimate AIM Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AIM Vaccine has a P/E ratio of -27.0x.
See valuation multiples for AIM Vaccine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $590M | XXX | $590M | XXX | XXX | XXX |
| EV (current) | $763M | XXX | $763M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -103.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -28.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -27.0x | XXX | -16.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -43.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAIM Vaccine's last 12 month revenue growth is 81%
AIM Vaccine's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
AIM Vaccine's rule of 40 is -92% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AIM Vaccine's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AIM Vaccine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 81% | XXX | 80% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -92% | XXX | 76% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 91% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AIM Vaccine acquired XXX companies to date.
Last acquisition by AIM Vaccine was XXXXXXXX, XXXXX XXXXX XXXXXX . AIM Vaccine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AIM Vaccine founded? | AIM Vaccine was founded in 2011. |
| Where is AIM Vaccine headquartered? | AIM Vaccine is headquartered in Hong Kong. |
| How many employees does AIM Vaccine have? | As of today, AIM Vaccine has 1.5K+ employees. |
| Who is the CEO of AIM Vaccine? | AIM Vaccine's CEO is Mr. Yan Zhou. |
| Is AIM Vaccine publicy listed? | Yes, AIM Vaccine is a public company listed on HKG. |
| What is the stock symbol of AIM Vaccine? | AIM Vaccine trades under 06660 ticker. |
| When did AIM Vaccine go public? | AIM Vaccine went public in 2022. |
| Who are competitors of AIM Vaccine? | Similar companies to AIM Vaccine include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of AIM Vaccine? | AIM Vaccine's current market cap is $590M |
| What is the current revenue of AIM Vaccine? | AIM Vaccine's last 12 months revenue is $204M. |
| What is the current revenue growth of AIM Vaccine? | AIM Vaccine revenue growth (NTM/LTM) is 81%. |
| What is the current EV/Revenue multiple of AIM Vaccine? | Current revenue multiple of AIM Vaccine is 4.1x. |
| Is AIM Vaccine profitable? | Yes, AIM Vaccine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
